High-dose intravenous gammaglobulin for chronic inflammatory demyelinating polyneuropathy.
We report our preliminary experience of high-dose intravenous gammaglobulin in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) selected for inefficacy or severe side effects of steroid and immunosuppressive treatment. Our treatment proved safe and effective, reversing the disability of CIDP, the improvement being temporally related to the commencement of intravenous high-dose gammaglobulin. The possible mechanisms of action are discussed.
D000328:Adult; D001369:Axons / Q000473:pathology; D003711:Demyelinating Diseases / Q000473:pathology / Q000628:therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D016756:Immunoglobulins, Intravenous; D008297:Male; D008875:Middle Aged; D009413:Nerve Fibers, Myelinated / Q000473:pathology; D011115:Polyneuropathies / Q000473:pathology / Q000628:therapy*; D011129:Polyradiculoneuropathy / Q000473:pathology / Q000628:therapy*
D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous